(NASDAQ: TLX) Telix Pharmaceuticals's forecast annual revenue growth rate of 37.59% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Telix Pharmaceuticals's revenue in 2025 is $492,583,018.On average, 3 Wall Street analysts forecast TLX's revenue for 2025 to be $274,941,353,081, with the lowest TLX revenue forecast at $269,208,861,551, and the highest TLX revenue forecast at $280,164,393,945. On average, 3 Wall Street analysts forecast TLX's revenue for 2026 to be $359,398,030,963, with the lowest TLX revenue forecast at $350,727,662,628, and the highest TLX revenue forecast at $368,565,130,434.
In 2027, TLX is forecast to generate $426,620,749,285 in revenue, with the lowest revenue forecast at $406,740,457,948 and the highest revenue forecast at $453,417,787,381.